A5019206374- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Eosinophilic Disorders and Syndromes
- Acute Myeloid Leukemia Research
- Testicular diseases and treatments
- Silk-based biomaterials and applications
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Click Chemistry and Applications
- Synthesis and biological activity
- Synthesis of Tetrazole Derivatives
- RNA Interference and Gene Delivery
- Acute Lymphoblastic Leukemia research
- Spectroscopy Techniques in Biomedical and Chemical Research
- Sarcoma Diagnosis and Treatment
- Digital Imaging for Blood Diseases
- Neuroblastoma Research and Treatments
- Immune Cell Function and Interaction
- Lymphoma Diagnosis and Treatment
Helios Salud
2020-2024
Hospital Italiano La Plata
2016-2024
Academia Nacional de Medicina
1997
Chronic myeloid leukemia (CML) is a stem cell neoplasm characterized by an expansion of progenitor cells and the presence BCR-ABL1 oncoprotein. Since introduction specific tyrosine kinase inhibitors (TKI), overall survival has improved significantly. However, under long-term therapy patients may have residual disease that originates from TKI-resistant leukemic (LSC). In this work, we analyzed miRNome LSC-enriched CD34 + CD38 − CD26 normal hematopoietic (HSC) fractions obtained same chronic...
508 Background: Germ cell tumors (GCTs) are the most common type of cancer in adolescent and young adult males. Most them curable with multimodal treatment: platinum-based chemotherapy (CT) + surgery. Patients who fail first-line treatment usually receive salvage CT response rates between 30 50%. High-dose autologous hematopoietic stem transplantation (HDCT) is an effective this context. Methods: We conducted a multicenter retrospective analysis patients ≥ 15 years old relapsed/refractory...
Abstract Chronic myeloid leukemia (CML) is a stem cell neoplasm characterized by an expansion of progenitor cells and the presence BCR-ABL1 oncoprotein. Since introduction specific tyrosine kinase inhibitors (TKI), overall survival has improved significantly. However, under long-term therapy patients may have residual disease that originates from TKI-resistant leukemic (LSC). In this work, we analyzed miRNome CML LSC, normal hematopoietic (HSC) obtained same patients, healthy donors (HD)...
Quantification of BCR-ABL1 mRNA levels in peripheral blood chronic myeloid leukemia patients is a strong indicator response to tyrosine-kinase inhibitors (TKI) treatment. However, additional prognostic markers are needed order better classify patients. The hypothesis leukemic stem cells (LSCs) heterogeneity and persistence, suggests that their functional evaluation could be clinical interest. In this work, we assessed the primitive progenitor fractions at diagnosis during TKI treatment using...